Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 361 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

Table of Contents
Year : 2013  |  Volume : 17  |  Issue : 6  |  Page : 977-982

Management of statin intolerance

1 Care Hospital, The Institute of Medical Sciences, Hyderabad, India
2 Department of Cardiology, St John's Medical College and Hospital, Bangalore, India
3 Medical Affairs, AstraZeneca India, Bangalore, India

Date of Web Publication3-Dec-2013

Correspondence Address:
K Madhu
Medical affairs, AstraZeneca
Login to access the Email id

Source of Support: Astra Zeneca wrt to medical writing support,, Conflict of Interest: None

DOI: 10.4103/2230-8210.122602

Rights and Permissions

Statins are the revolutionary drugs in the cardiovascular pharmacotherapy. But they also possess several adverse effects like myopathy with elevation of hepatic transaminases (>3 times the upper limit of normal) or creatine kinase (>10 times the upper limit of normal) and some rare side-effects, including peripheral neuropathy, memory loss, sleep disturbances, and erectile dysfunction. Due to these adverse effects, patients abruptly withdrew statins without consulting physicians. This abrupt discontinuation of statins is termed as statin intolerance. Statin-induced myopathy constitutes two third of all side-effects from statins and is the primary reason for statin intolerance. Though statin intolerance has considerably impacted cardiovascular outcomes in the high-risk patients, it has been well effectively managed by prescribing statins either as alternate-day or once weekly dosage regimen, as combination therapy with a non-statin therapy or and by dietary intervention. The present article reviews the causes, clinical implications of statin withdrawal and management of statin intolerance.

Keywords: Adverse effects of stains, myopathy, rhabdomyolysis, statins, statin intolerance

How to cite this article:
Raju SB, Varghese K, Madhu K. Management of statin intolerance. Indian J Endocr Metab 2013;17:977-82

How to cite this URL:
Raju SB, Varghese K, Madhu K. Management of statin intolerance. Indian J Endocr Metab [serial online] 2013 [cited 2021 Jul 24];17:977-82. Available from: https://www.ijem.in/text.asp?2013/17/6/977/122602

   Introduction Top

Statins or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have revolutionized cardiovascular pharmacotherapy. Though they have confirmed safety and efficacy profile, statins have reportedly been associated with several adverse effects forcing abrupt discontinuation without consulting their physician. [1] This is termed as statin intolerance. Statins were shown to adversely affect fatty acid oxidation, decrease sarcolemal cholesterol, deplete isoprenoid, disturb calcium homeostasis and lipid metabolism, cause autoimmune phenomena, increase intracellular lipids, and cause mitochondrial dysfunction due to inhibition of ubiquinone or coenzyme Q10 production, leading to emergence of statin-induced adverse effects [Table 1]. [2] The major statin-induced adverse effects are muscle-related complications (myalgia, myopathy, rhabdomyolysis), hepatotoxicity, nephrotoxicity (proteinuria), headache, rash, and gastrointestinal discomforts. [3],[4] These adverse effects manifest more severely in patients aged over 80 years, with liver and muscle disorders, chronic renal insufficiency with diabetes or hypothyroidism, or co-prescription of agents that compete with statins for metabolism such as fibrates, cyclosporine, warfarin, azole antifungals, macrolides, Human Immunodeficiency Virus (HIV) protease inhibitors, verapamil or amiodarone. [4] Predominantly, myalgia is considered as the leading cause of statin intolerance. [5],[6] Both myopathy and rhabdomyolysis constitute two thirds of statin adverse effects that warrant serious attention. Fatal incidence of rhabdomyolysis was considered as the major reason of cerivastatin withdrawal in 2001. [7] As per Food and Drug Administration, myopathy is defined as elevation of creatinine kinase (CK) up to 10-fold, myalgia as any pain in a muscle or group of muscles, and rhabdomyolysis as CK elevation >50-fold with severe skeletal muscle injury and lysis and myoglobinuria. Other rare adverse effects of statins-peripheral neuropathy, memory loss, erectile dysfunction, and sleep disturbances may also lead to statin intolerance [Table 3].
Table 1: Mechanism of major statin-induced adverse effects

Click here to view
Table 3: Effects of statin withdrawal

Click here to view

In clinical practice, statin intolerance poses a great hindrance to effective treatment in patients afflicted with cardiovascular disease, leading to statin discontinuation in 28.9% of patients within the first year of initiation of statin therapy. [8]

   How to Identify Statin Intolerance Top

Both statin-induced elevation of CK levels (defined as >10 times the Upper Limit of Normal [ULN]) and hepatic transaminases (defined as >3 times the ULN) have been reported as good predictors of serious statin-adverse effects. [9]

Assessment of creatine kinase in statin-induced myopathy

Statin-induced myopathy is a class effect of statins which tends to progress to rhabdomyolysis at higher doses of statins. Myopathy/rhabdomyolysis is usually precipitated when statins are co-prescribed with interacting drugs, including fibrates and the inhibitors and inducers of hepatic microsomal enzymes (cytochrome P450) which included cyclosporine A, azole antifungals, fibrates, niacin, protease inhibitors, macrolide antibiotics, calcium channel blockers, warfarin, and grapefruit juice. [10] Routine CK assessment was not found useful in detecting rare cases of myopathy in patients who were on the standard statin doses. [11] Statin product information mentions that patients who experienced any new or unexplained muscle pain or weakness must report to their physician and recommended CK assessment in these patients [Figure 1]. In addition, patients with muscle weakness or bilateral proximal muscle pain, excluding other known causes have also been recommended to have their CK assessed. Patients with CK level >10 times the ULN most likely suffer from myopathy and have brown discoloration of urine, which serves as an indicator of overall elevation of myoglobin in the blood. These patients with myopathy have elevated levels of transaminases which normalise on improvement of myopathy. With increase in awareness of drug interactions, statin intolerance could be prevented [Table 2].
Figure 1: Statin-induce myopathy management

Click here to view
Table 2: Important statin drug interactions causing statin intolerance

Click here to view

Assessment of hepatic transaminases

Product information of statins mentions the baseline measurement of hepatic enzymes such as ALT (Alanine aminotransferase) and AST (aspartate aminotransferase) and forbids use of statins in active liver diseases. [12] Therefore, patients with baseline liver abnormalities and active disease should refrain from using statins. Generally, at a clinical dose of statins, there is rare (<1%) elevation of hepatic enzymes but at higher doses the level of hepatic enzyme increases with differing intensity depending on the type of statin.

Routine assessment of hepatic transaminases is no longer required for simvastatin, pravastatin, or lovastatin up to 40 mg/day but is recommended for other statins and for higher doses of statins. If ALT or AST levels are >3 times the ULN in an asymptomatic patient with other liver abnormalities, the liver function test should be done within a week and statins must be stopped temporarily if ALT level did not fall to the normal level. [12] In 2006, the Liver Expert Panel reported that they did not find any proof that statins caused life-threatening liver damage and elevation of hepatic enzymes reversed after stopping statin. The panel did not recommend routine evaluation but suggested repetition of the test in case the transaminases are >3 times ULN and further evaluation if it remains elevated. The statins should be discontinued only in the presence of any objective liver injury. [13]

   Management of Statin Intolerance Top

The first step in the strategy to manage statin intolerance is to rule out extraneous factors that may increase the risk of myopathy/rhabdomyolysis or elevate hepatic transaminases. The National Lipid Association Statin Safety Task Force has prescribed guidelines to manage statin intolerance [Figure 1].

Other strategies used to manage statin intolerance are switching therapy, alternate day dosing, non-statin lipid-lowering drugs, lipid lowering nutraceuticals, and specific pharmacotherapies which are detailed below.

Switching therapy

This strategy of switching therapy is effective in only some patients since the criteria to select the new statins are not clearly delineated. [14],[15] Switching from 1) Mild to high lipophilic statin 2) from cytochrome P450 metabolised to non-cytochrome P450 metabolised statin, and 3) to a lower dosage of a more potent statin have been utilised. A prospective, open-label pilot study evaluated the effectiveness and safety profile of rosuvastatin (newer and a highly potent non-cytochrome P450 metabolised statin) at 5 and 10 mg/day doses in patients with primary high LDL-C (mean, 177 mg/dL) and intolerance to other statins due to myalgia. [16]

In moderately high risk patient 5 mg/day rosuvastatin was prescribed and 10 mg/day was prescribed to high or very high risk patients. It was noted after 36 weeks that 5 mg/day rosuvastatin dose reduced LDL-C by 42% and 10 mg/day by 39%. Only one patient who was receiving 10 mg/day rosuvastatin dose discontinued rosuvastatin treatment due to unilateral muscular pain after 4 weeks with no significant elevation in hepatic enzymes.

Alternate day dosing

Statins with longer half-life maintain lipid lowering effect over a longer period of time, enabling alternate day dosing strategy with statin. Atorvastatin with a mean half-life of 14 hrs is metabolised into two active metabolites-orthohydroxy and parahydroxy forms. Both these active metabolites contribute to 70% activity of atorvastatin and have a half-life of 20 to 30 hrs. [17] This pharmacokinetic parameter of atorvastatin makes it suitable for an alternate-day dosage regimen and continues its lipid lowering activity for considerably a longer period of time. Rosuvastatin, a third generation statin, possess a long half-life period of around 19hrs. Two patients who developed intolerance to daily atorvastatin therapy, due to myalgia, were subsequently treated with rosuvastatin (at a dosage of 2.5 mg and 5 mg) on 1 st , 3 rd , and 5 th days of the week, respectively. At both the doses, the level of LDL-C decreased by 38% and 20%, respectively with the resolution of adverse effects after six weeks of treatment. [18] In 2008, Gadarla et al., reported use of rosuvastatin (5 and 10 mg), two-times a week (on the first and fourth day of the week) for a period longer than three weeks in patients aged 62-70 years who developed myopathy due to other lipid-lowering therapy. [19] The rosuvastatin dosage regimen was well accepted by 80% of the patients with significant 26% LDL-C reduction from the baseline. In another study, eight patients who were intolerant to daily statin responded well with once-weekly dosage of rosuvastatin (5-20 mg) and reported a mean LDL-C reduction of 29%. [20] The apparent reasons for weekly statin regimen tolerance could be due to either lowering of overall plasma concentration of statins or psychological reasons. However, this alternate day dosing strategy had certain limitation. First, alternate day statin dose administration causes a lower LDL-C reduction (up to 10-15% less) compared to daily dose regimen in high-risk patients. However, this LDL-C reduction was much lower than the ideal LDL-C target set for each high-risk patient. Second, alternate-day dosing strategy has not been established through clinical trials. Thus alternate day dosing strategy should be used only as a secondary option in specific high-risk patients who are intolerant to lower statin dosage.

Non statin lipid-lowering drugs

Non-statin lipid lowering drugs include a bile acid sequestrant (colesevelam), an intestinal cholesterol absorption inhibitor (ezetimibe), fibrates, and niacin which may be either used alone or in combination. These drugs have been considered in cases of unmanaged statin intolerance. Co-administration of ezetimibe and bile acid sequestrants (colesevelam, colestipol, or cholestyramine) yields additional reduction of LDL-C levels without any adverse effects in comparison to stable bile acid sequestrant regimen alone. Addition of ezetimibe to nicotinic acid lowers LDL-C levels without modifying nicotinic acid-induced increase of HDL-C. The triple therapy i.e. bile acid sequestrant, statin, and ezetimibe or nicotinic acid further reduces LDL-C levels. However, no clinical outcome studies with these combinations have been performed. Functional food containing phytosterols or plant sterol containing tablets have been reported to reduce LDL-C levels up to 5-10% in patients taking a stable dose of a statin. This combination of plant sterol and statins was have been reported as well tolerated and safe. [21],[22] Since no clinical trials with combination of plant sterols and other lipid-lowering drugs have been established for CVD outcomes, their efficacy in CVD risk reduction remains speculative.

Use of lipid lowering nutraceuticals

Various dietary interventions, including foods low in saturated fat and high in viscous fibers (e.g., oats and barley), plant sterols, vegetable protein foods (soy), and nuts (e.g., almonds) have been used in patients who cannot tolerate statins. The efficacy of these dietary interventions was further strengthened by addition of nutraceuticals such as red yeast. [23] In 2003, Jenkins and colleagues reported that dietary portfolio of cholesterol-lowering foods caused cholesterol lowering effect comparable to a statin. But due to its limitation of palatability, dietary supplements were used as an alternative option. [24] Chinese red yeast rice is a dietary supplement made by fermenting the yeast, Monascus purpureus, over rice. Monascus yeast produces a family of substances called monacolins capable of inhibiting the enzyme HMG-CoA reductase and also contains unsaturated fatty acids and phytosterols. Red yeast rice offers only modest LDL-C lowering (up to 20%) and has been prescribed to only low-risk individuals or in whom LDL-C level is not far from the target. [25]

Specific Pharmacotherapies

Presently, there is a lack of consensus on the use of specific pharmacotherapy for statin-induced myopathy. Coenzyme Q10 (CoQ10) deficiency has been correlated with the development of myopathy. Various studies have reported significant improvement in statin-induced adverse effects-myopathy, myalgia, peripheral neuropathy, fatigue, dyspnoea, and memory loss if coenzyme Q10 was given as a co-therapy with statins. [26],[27],[28],[29],[30] In 2009, Kalra et al., [5] reported that coenzyme Q10 (200 mg/day) supplementation in statin-treated patients would help in preventing statin-induced adverse effects, leading to low statin intolerance and maximal benefits of statin.

Vitamin deficiency has been associated with myalgia and poor muscle function and its supplementation have shown ameliorative effects in statin induced myopathy. A recent trial has shown that 92% of patients become myalgia free after three months of vitamin D supplementation. [31]

   Conclusion Top

In recent years, increasing complaints of intolerance to statins have considerably impacted outcomes, especially in high-risk patients. Furthermore, several studies have reported negative consequences of acute statin withdrawal on cardiac patients, especially the patients with ACS and stroke. Increased understanding of statin-induced adverse-effects and awareness of clinical implications of acute statin withdrawal has discouraged patients from abrupt discontinuation of statin therapy. Statin intolerance has been effectively managed either by the use of alternate-day statin regimen with longer half lives like atorvastatin and rosuvastatin, combination of statins with non-statins, dietary interventions, or by specific pharmacotherapies.

   Acknowledgement Top

Max Neeman International, New Delhi, was responsible for preparation of the review article.

   References Top

1.Gotto AM. Statins, cardiovascular disease, and drug safety. Am J Cardiol 2006;97:3C-5.  Back to cited text no. 1
2.Abd TT, Jacobson TA. Statin induced myopathy: A review and myopathy. Expert Opin Drug Saf 2011;10:373-87.  Back to cited text no. 2
3.Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins-mechanism and consequences. Curr Drug Saf 2009; 4:209-28.  Back to cited text no. 3
4.Stone NJ. Stopping statins. Circulation 2004;110:2280-2.  Back to cited text no. 4
5.Kalra S, Agrawal N, Kalra B, Sharma A, Kamboj R. The role of Coenzyme Q10 in statin associated myopathy. Electron Physic 2009;1:2-8.  Back to cited text no. 5
6.Jacobson TA. Toward pain free statin prescribing algorithm for diagnosis and management of mayalgia. Mayo Clin Proc 2008;83:687-700.  Back to cited text no. 6
7.Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis [letter]. N Engl J Med 2002;346:539-40.  Back to cited text no. 7
8.Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007;99:530-4.  Back to cited text no. 8
9.Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Proceedings of a canadian working group consensus conference. Canad J Cardiol 2011;27:635-62.  Back to cited text no. 9
10.Bellosta S, Paoletti R, Corsinin A. Safety of statins: Focus on clinical pharmacokinetics and drug interaction. Circulation 2004;109:III50-7.  Back to cited text no. 10
11.Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90.  Back to cited text no. 11
12.Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: A molehill, an iceberg, or neither. Hepatology 2008;48:662-9.  Back to cited text no. 12
13.Cohen DE, Anania FA, Chalasani N. Assessment of statin safety by hepatologists. Am J Cardiol 2006;97:77c-81.  Back to cited text no. 13
14.Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165:2671-6.  Back to cited text no. 14
15.Arca M, Pigna G. Treating statin intolerant patients. Diab Metab Synd Obes Targ Ther 2011;4:1555-66.  Back to cited text no. 15
16.Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, et al. Rosuvastatin 5 and 10 mg/d: A pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL. Clin Ther 2006;28:933-42.  Back to cited text no. 16
17.Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephro Dial Transplant 2003;18:967-76.  Back to cited text no. 17
18.Mackie BD, Satija S, Nell C, Miller J, Sperling LS. Monday, wednesday and friday dosing of rosuvastatin in patients intolerant to statin therapy. Am J Cardiol 2007;99:291.  Back to cited text no. 18
19.Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008;101:1747-48.  Back to cited text no. 19
20.Bakes JM, Vernero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008;42:341-6.  Back to cited text no. 20
21.Abumweis SS, Barake R, Jones PJ. Plant sterols/stanols as cholesterol lowering agents: A meta-analysis of randomized controlled trials. Food Nutr Res 2008;52: in press.  Back to cited text no. 21
22.ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-18.  Back to cited text no. 22
23.Carter M, O'Keefe JH. Is red yeast rice a suitable alternative for statins. Mayo Clin Proc 2008;83:1294.  Back to cited text no. 23
24.Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003;290:502-10.  Back to cited text no. 24
25.Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 2000;48:5220-5.  Back to cited text no. 25
26.Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2:483-91.  Back to cited text no. 26
27.Kim WS, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001;19:81-3.  Back to cited text no. 27
28.Langsjoen PH, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplementation of Coenzyme Q 10 and statin drug discontinuation. Bio Factors 2005;25:147-52.  Back to cited text no. 28
29.Schaars CF, Stalenhoef AF. Effects of ubiquinone (Coenzyme Q10) in myopathy in statin users. Curr Opin Lipidol 2008;19:553-7.  Back to cited text no. 29
30.Kelly P, Vasu S, Getato M, McNurlan M, Lawson WE. Coenzyme Q10 improves myopathic pain in statin treated patients J Am Coll Cardiol 2005;45:3A.  Back to cited text no. 30
31.Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25 (OH) vitamin D levels (32 ng/mL) are associated with reversible myositis myalgia in statin-treated patients. Transl Res 2009;153:11-6.  Back to cited text no. 31


  [Figure 1]

  [Table 1], [Table 2], [Table 3]

This article has been cited by
1 Pharmacogenetics of Statin-Induced Myotoxicity
Ping Siu Kee,Paul Ken Leong Chin,Martin A. Kennedy,Simran D. S. Maggo
Frontiers in Genetics. 2020; 11
[Pubmed] | [DOI]
2 Statins-related peripheral neuropathy among diabetic patients
Mohamed A. Hammad,Syed Azhar Syed Sulaiman,Saleh Alghamdi,Altaf Ali Mangi,Nor Azizah Aziz,Dzul Azri Mohamed Noor
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;
[Pubmed] | [DOI]
3 Statins: Complex outcomes but increasingly helpful treatment options for patients
Niloufar Mohammadkhani,Sedigheh Gharbi,Huda Fatima,Avishan Farzaneh,Golnoosh Mahjoob,Afsaneh Hoseinsalari,Eberhard Korsching
European Journal of Pharmacology. 2019; : 172704
[Pubmed] | [DOI]
4 Future perspectives of the pharmacological management of diabetic dyslipidemia
Angelo Maria Patti,Rosaria Vincenza Giglio,Nikolaos Papanas,Manfredi Rizzo,Ali A. Rizvi
Expert Review of Clinical Pharmacology. 2019; 12(2): 129
[Pubmed] | [DOI]
5 Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components
Richard Myles Turner,Munir Pirmohamed
Journal of Clinical Medicine. 2019; 9(1): 22
[Pubmed] | [DOI]
6 Geranylgeraniol prevents statin-induced skeletal muscle fatigue without causing adverse effects in cardiac or vascular smooth muscle performance
Jordon C. Irwin,Andrew S. Fenning,Rebecca K. Vella
Translational Research. 2019;
[Pubmed] | [DOI]
7 Statin Intolerance: an Overview of the Current Status and Possible Treatment Options
Sunghwan Suh,Chang Hee Jung,Soon-Jun Hong,Jung-Sun Kim,Sung Hee Choi
Journal of Lipid and Atherosclerosis. 2018; 7(2): 77
[Pubmed] | [DOI]
8 Understanding Patient Adherence and Concerns with STatins and MedicatION Discussions With Physicians (ACTION): A survey on the patient perspective of dialogue with healthcare providers regarding statin therapy
Eliot A. Brinton
Clinical Cardiology. 2018; 41(6): 710
[Pubmed] | [DOI]
9 Management of Statin Intolerance in 2018: Still More Questions Than Answers
Peter P. Toth,Angelo Maria Patti,Rosaria Vincenza Giglio,Dragana Nikolic,Giuseppa Castellino,Manfredi Rizzo,Maciej Banach
American Journal of Cardiovascular Drugs. 2018;
[Pubmed] | [DOI]
10 Satisfaction With Statin Treatment Among Adult Coronary Artery Disease Patients: An Experience From a Resource-Constrained Setting
Rubina Mulchandani,Tanica Lyngdoh,Praloy Chakraborty,Ashish Kumar Kakkar
Heart, Lung and Circulation. 2018;
[Pubmed] | [DOI]
11 The reno-protective effects of atorvastatin in crush syndrome and rhabdomyolysis:is there a dilemma?
[Pubmed] | [DOI]
12 Statin intolerance – a question of definition
Engi Abdel-Hady Algharably,Iris Filler,Stephanie Rosenfeld,Katja Grabowski,Reinhold Kreutz
Expert Opinion on Drug Safety. 2017; 16(1): 55
[Pubmed] | [DOI]
13 Statin related adverse effects and patient education: a study from resource limited settings
Rubina Mulchandani,Tanica Lyngdoh,Praloy Chakraborty,Ashish Kumar Kakkar
Acta Cardiologica. 2017; : 1
[Pubmed] | [DOI]
14 Atorvastatin and metformin administration modulates experimental Trichinella spiralis infection
Ahmad A. Othman,Dina M. Abou Rayia,Dalia S. Ashour,Eman M. Saied,Doaa H. Zineldeen,Ahmad A. El-Ebiary
Parasitology International. 2016; 65(2): 105
[Pubmed] | [DOI]
15 Expert opinion: the therapeutic challenges faced by statin intolerance
Jaideep Patel,Seth S Martin,Maciej Banach
Expert Opinion on Pharmacotherapy. 2016; : 1
[Pubmed] | [DOI]
16 Statin-induced rhabdomyolysis mimicking polymyositis on18F-FDG PET imaging
H. Yildiz,V. Roelants,P. Hainaut
Acta Clinica Belgica. 2015; 70(2): 151
[Pubmed] | [DOI]
17 Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
Maciej Banach,Manfredi Rizzo,Peter P Toth,Michel Farnier,Michael H Davidson,Khalid Al-Rasadi,Wilbert S Aronow,Vasilis Athyros,Dragan M Djuric,Marat V Ezhov,Robert S Greenfield,G Kees Hovingh,Karam Kostner,Corina Serban,Daniel Lighezan,Zlatko Fras,Patrick M Moriarty,Paul Muntner,Assen Goudev,Richard Ceska,Stephen J Nicholls,Marlena Broncel,Dragana Nikolic,Daniel Pella,Raman Puri,Jacek Rysz,Nathan D Wong,Laszlo Bajnok,Steven R Jones,Kausik K Ray,Dimitri P Mikhailidis
Expert Opinion on Drug Safety. 2015; 14(6): 935
[Pubmed] | [DOI]
18 Statin Alternatives: A Review of Over-the-Counter Lipid-Lowering Supplements
Joseph V. Danavi,Shermeen B. Memon,Binh An P. Phan
Alternative and Complementary Therapies. 2015; 21(5): 198
[Pubmed] | [DOI]
19 Management of dyslipidaemia in statin-intolerant patients in light of AHA and NPA guidelines of 2013–2014
Soumya Patnaik,Amar Narayan Patnaik
Journal of Indian College of Cardiology. 2015; 5(2): 119
[Pubmed] | [DOI]
20 Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management
Physiological Research. 2014; : S327
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    How to Identify ...
    Management of St...
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded961    
    Comments [Add]    
    Cited by others 20    

Recommend this journal